StockpollyBeta
Get App
Delisting riskPopularity #3,932
ONCY · NASDAQ · Biotechnology

Oncolytics Biotech (ONCY)

Develops pelareorep, a double-stranded RNA immunotherapy for gastrointestinal tumors.

$0.6718
vs last close−0.04 (−5.82%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
899810554101099
Research & development456572325354
443332224755
General & administrative043332224755
Other expenses000000000000
Operating income−8−9−9−8−10−5−5−4−10−10−9−9
15210000−1100
Interest income000000000000
Other non-operating income−100000000000
Income before tax−7−4−7−7−10−5−5−4−11−9−9−9
Income tax expense000000000000
Net income from continuing operations−7−4−7−7−10−5−5−5−10−9−9−9
Net income−7−4−7−7−10−5−5−5−10−9−9−9
EPS, basic−$0.14−$0.05−$0.09−$0.10−$0.12$0.01−$0.08−$0.07−$0.14−$0.01−$0.11−$0.08
EPS, diluted−$0.14−$0.05−$0.09−$0.10−$0.12$0.01−$0.08−$0.07−$0.14−$0.01−$0.11−$0.08
Weighted average shares, basic7074757677808591101108112120
Weighted average shares, diluted7074757677808591101108112120
EBITDA−7−9−9−8−10−5−5−4−10−10−9−9
Depreciation & amortization000000000000
EBIT−7−9−9−8−10−5−5−4−10−10−9−9